Levothyroxine PO to IV Conversion
When converting levothyroxine from oral to intravenous administration, give 70% or less of the usual oral dose intravenously 1.
Conversion Rationale
The 70% conversion factor is based on the bioavailability difference between routes:
- Oral levothyroxine has approximately 70% absorption from the gastrointestinal tract
- IV levothyroxine has 100% bioavailability (direct bloodstream delivery)
- Therefore, a lower absolute dose IV achieves equivalent systemic exposure
Practical Conversion Algorithm
Step 1: Calculate the IV dose
- Take the patient's current oral daily dose
- Multiply by 0.70 (or less for conservative approach)
- Example: 100 mcg PO daily → 70 mcg IV daily (or start at 50 mcg IV for safety)
Step 2: Administration method
- Dilute calculated dose in 100 mL of 0.9% NaCl containing 1% albumin 2
- Give by slow IV drip infusion
- Can be administered once daily
Step 3: Monitoring
- Check TSH and free T4 after 4-8 weeks of stable dosing 1
- Monitor for cardiac symptoms (tachycardia, arrhythmias, chest pain) especially in elderly or those with cardiac disease 3
- Adjust dose in 12.5-25 mcg increments as needed
Clinical Indications for IV Route
IV levothyroxine is appropriate when oral administration is impossible 1, 4:
- Esophageal obstruction (stricture, cancer, severe dysphagia)
- Altered consciousness (coma, sedation in ICU)
- Gastrointestinal dysfunction (severe malabsorption, ileus, shock)
- Myxedema coma (medical emergency requiring IV therapy for 3-10 days until oral intake possible) 4
- NPO status when enteral feeding cannot be interrupted 1
Important Safety Considerations
Cardiac Precautions
Exercise extreme caution in patients with cardiovascular disease or age >50-60 years 3:
- Start at lower doses (consider 50% of calculated dose initially)
- Monitor closely for angina, arrhythmias, increased heart rate
- IV route produces higher peak T4 and T3 levels than oral 5
- Risk of precipitating cardiac events is real, especially with rapid correction
Adrenal Insufficiency
Critical pitfall: In patients with potential adrenal insufficiency (autoimmune polyglandular syndrome, pituitary disease):
- Must treat with glucocorticoids BEFORE initiating levothyroxine 3
- Thyroid hormone increases metabolic clearance of cortisol
- Failure to do so may precipitate acute adrenal crisis
Alternative When IV Unavailable
If IV levothyroxine is not available 1:
- Crush oral levothyroxine tablets and suspend in water
- Administer via nasogastric or feeding tube
- Stop enteral feeding for as long as possible before dose
- Resume feeding at least 1 hour after administration
Duration of IV Therapy
Transition back to oral as soon as feasible:
- Most patients: 3-10 days IV until oral intake restored 4
- Once gastrointestinal function normalizes, resume oral dosing at pre-conversion dose
- No need for gradual transition—can switch directly from IV to oral
Special Populations
Myxedema coma: Higher initial doses may be used (500-1000 mcg IV loading dose has been reported) 5, but this is controversial and carries significant cardiac risk. Standard approach uses more conservative dosing with the 70% rule.
Weekly dosing: For compliance issues, weekly IV administration (300 mcg) or oral administration (700 mcg) has been reported as safe and effective 6, though this is not standard practice and requires specialized monitoring.
The 70% conversion rule from the AACE/ATA guidelines 1 represents the most authoritative and widely accepted approach, balancing efficacy with safety across diverse patient populations.